Confused between eczema and psoriasis? Experts explain how these skin conditions differ in symptoms, causes, and treatment.
A TYK2 inhibitor in development shows superior efficacy to placebo and apremilast for treating psoriasis, with no new safety ...
Once-daily oral zasocitinib for moderate to severe plaque psoriasis demonstrated rapid and durable skin clearance and a ...
Understand how step therapy affects psoriasis treatment. Learn about the ‘fail first’ process, the impact of treatment delays ...
One-year Phase 3 data for ICOTYDE to be presented at AAD 2026 demonstrate lasting skin clearance and a favorable safety ...
Envudeucitinib, another allosteric TYK2 inhibitor, also achieved PASI 75 in 70-75% of patients at 16 weeks and PGA 0/1 status ...
IFPA (The International Federation of Psoriasis Associations) – is convening the first-ever regional summit dedicated exclusively to psoriasis in Africa - one of the continent's most underrecognized ...
Envudeucitinib achieved robust PASI responses by Week 16, with significant continued improvements by Week 24 in PASI 90 (68.0%, 62.1%) and PASI ...
In a new study in mice published on Thursday in Science, researchers showed how skin cells inherit patterns of gene ...
Skin conditions such as psoriasis often flare up in the same spots throughout one’s life. Now scientists think they know why ...
Nonsteroidal topicals like roflumilast are enabling proactive, long-term psoriasis control across a broad range of patients, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results